ArticleCancer biomarkers : section A of Disease markers2016
Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.
Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Lipid Metabolic Reprogramming in Lung Cancer: Mechanisms and Therapeutic Targets in the Tumor Microenvironment.International journal of cancer · 2026Review
- Plasma metabolites as biomarkers for screening and differential diagnosis of lung cancer.Journal of cardiothoracic surgery · 2025Article
- Metabolomic profiling reveals distinct lipid signatures in progressive versus stable fibrotic lung disease.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice.Life (Basel, Switzerland) · 2025Article
- Glycerophospholipids in Red Blood Cells Are Associated with Aerobic Performance in Young Swimmers.Nutrients · 2024Article
- Causal association of plasma lipidome with lung carcinoma and mediating role of inflammatory proteins: evidence from Mendelian randomization analysis.Journal of Cancer · 2024Article
- Biomarkers of lung cancer for screening and in never-smokers-a narrative review.Translational lung cancer research · 2023Review
- Review
- Metabolomic differentiation of benign vs malignant pulmonary nodules with high specificity via high-resolution mass spectrometry analysis of patient sera.Nature communications · 2023Article
- The Landscape of Lipid Metabolism in Lung Cancer: The Role of Structural Profiling.Journal of clinical medicine · 2023Article
- Comprehensive plasma metabolomics and lipidomics of benign and malignant solitary pulmonary nodules.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Imputation of Missing Values for Multi-Biospecimen Metabolomics Studies: Bias and Effects on Statistical Validity.Metabolites · 2022Article
- Plasm Metabolomics Study in Pulmonary Metastatic Carcinoma.Journal of oncology · 2022Article
- Metabolic Changes in Early-Stage Non-Small Cell Lung Cancer Patients after Surgical Resection.Cancers · 2021Article
- Ongoing challenges in implementation of lung cancer screening.Translational lung cancer research · 2021Review
- Mathermycin, an anti-cancer molecule that targets cell surface phospholipids.Toxicology and applied pharmacology · 2021Article
- Predicting human health from biofluid-based metabolomics using machine learning.Scientific reports · 2020Article
- Noninvasive biomarkers for lung cancer diagnosis, where do we stand?Journal of thoracic disease · 2020Review
- Toward Complete Structure Elucidation of Glycerophospholipids in the Gas Phase through Charge Inversion Ion/Ion Chemistry.Analytical chemistry · 2020Article
- Early diagnosis and screening in lung cancer.American journal of cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundRecent computed tomography (CT) screening trials showed that it is effective for early detection of lung cancer, but were plagued by high false positive rates. Additional blood biomarker tests designed to complement CT screening and reduce false positive rates are highly desirable.
objectiveIdentify blood-based metabolite biomarkers for diagnosing lung cancer. MEHTODS: Serum samples from subjects participating in a CT screening trial were analyzed using untargeted GC-TOFMS and HILIC-qTOFMS-based metabolomics. Samples were acquired prior to diagnosis (pre-diagnostic, n= 17), at-diagnosis (n= 25) and post-diagnosis (n= 19) of lung cancer and from subjects with benign nodules (n= 29).
resultsUnivariate analysis identified 40, 102 and 30 features which were significantly different between subjects with malignant (pre-, at- and post-diagnosis) solitary pulmonary nodules (SPNs) and benign SPNs, respectively. Ten metabolites were consistently different between subjects presenting malignant (pre- and at-diagnosis) or benign SPNs. Three of these 10 metabolites were phosphatidylethanolamines (PE) suggesting alterations in lipid metabolism. Accuracies of 77%, 83% and 78% in the pre-diagnosis group and 69%, 71% and 67% in the at-diagnosis group were determined for PE(34:2), PE(36:2) and PE(38:4), respectively.
conclusionsThis study demonstrates evidence of early metabolic alterations that can possibly distinguish malignant from benign SPNs. Further studies in larger pools of samples are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.